Tuesday, November 6, 2018
Lilly CFO: Will consider more acquisitions like Armo
Eli Lilly CFO Joshua Smiley told Reuters in an interview that his company will consider more acquisitions similar to its $1.6B purchase of cancer drug developer Armo BioSciences earlier this year. Smiley added, however, that mergers with big drug companies were unlikely to be an important tool to grow in the future.
https://thefly.com/landingPageNews.php?id=2818489
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.